HK1129063A1 - Tumor-targeted nanodelivery systems to improve early mri detection of cancer - Google Patents

Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Info

Publication number
HK1129063A1
HK1129063A1 HK09106582.2A HK09106582A HK1129063A1 HK 1129063 A1 HK1129063 A1 HK 1129063A1 HK 09106582 A HK09106582 A HK 09106582A HK 1129063 A1 HK1129063 A1 HK 1129063A1
Authority
HK
Hong Kong
Prior art keywords
tumor
cancer
improve early
mri detection
targeted
Prior art date
Application number
HK09106582.2A
Other languages
English (en)
Inventor
Esther H Chang
Kathleen F Pirollo
Original Assignee
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgetown filed Critical Univ Georgetown
Publication of HK1129063A1 publication Critical patent/HK1129063A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09106582.2A 2005-10-20 2009-07-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer HK1129063A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72830305P 2005-10-20 2005-10-20
PCT/US2006/041139 WO2007047981A2 (en) 2005-10-20 2006-10-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Publications (1)

Publication Number Publication Date
HK1129063A1 true HK1129063A1 (en) 2009-11-20

Family

ID=37963345

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09106582.2A HK1129063A1 (en) 2005-10-20 2009-07-20 Tumor-targeted nanodelivery systems to improve early mri detection of cancer

Country Status (8)

Country Link
JP (1) JP5478886B2 (xx)
KR (1) KR20080064169A (xx)
CN (1) CN101351225B (xx)
AU (1) AU2006304790B2 (xx)
CA (1) CA2638899C (xx)
HK (1) HK1129063A1 (xx)
IL (1) IL190773A (xx)
WO (1) WO2007047981A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801344A (zh) * 2007-07-09 2010-08-11 乔治敦大学 关于使用阳离子脂质体介导的核酸递送产生免疫应答的方法
US8320647B2 (en) 2007-11-20 2012-11-27 Olea Medical Method and system for processing multiple series of biological images obtained from a patient
KR101967417B1 (ko) 2008-11-10 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
CN102078624B (zh) * 2010-12-23 2012-07-25 华东理工大学 一种高效载钆脂质体制剂及其制备方法
WO2013031619A1 (ja) * 2011-08-26 2013-03-07 学校法人藤田学園 抗ヒトトランスフェリン受容体抗体を含む画像用腫瘍診断剤
US20140120157A1 (en) 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2806896C (en) * 2012-09-19 2021-06-15 Georgetown University Targeted liposomes prepared by ethanol injection
EP2968598B1 (en) * 2013-03-14 2020-05-27 Georgetown University Treatment for exposure to nerve agent
US20210077399A1 (en) * 2018-05-08 2021-03-18 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3902794B2 (ja) * 1997-03-07 2007-04-11 マックス−デルブルック−セントラム フュア モレクラーレ メディシン 特異的磁気体、その製造方法及び使用
US7780882B2 (en) * 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
CA2362550C (en) * 1999-02-22 2010-05-11 Georgetown University Antibody fragment-targeted immunoliposomes for systemic gene delivery
HUP0301835A2 (hu) * 2000-05-03 2003-09-29 Mbt Munich Biotechnology Ag Kationos diagnosztikai, képalkotó és terápiás ágensek, aktivált vaszkuláris helyekkel asszociálódva
WO2003084386A2 (en) * 2002-04-03 2003-10-16 See Jackie R Methods for ultrasonic imaging and treating diseased tissues
CA2513769A1 (en) * 2003-01-28 2004-08-12 Georgetown University Method for evaluating the efficacy of certain cancer treatments
CA2528411C (en) * 2003-06-04 2012-09-04 Georgetown University Method for improving stability and shelf-life of liposome complexes
JP2007528854A (ja) * 2003-07-09 2007-10-18 カリフォルニア パシフィック メディカル センター 細胞への物質送達の遠隔検出
JP2005170807A (ja) * 2003-12-09 2005-06-30 Fuji Photo Film Co Ltd 抗体を含むリポソーム

Also Published As

Publication number Publication date
WO2007047981A2 (en) 2007-04-26
JP5478886B2 (ja) 2014-04-23
CA2638899A1 (en) 2007-04-26
CN101351225A (zh) 2009-01-21
KR20080064169A (ko) 2008-07-08
WO2007047981A3 (en) 2007-10-25
JP2009512712A (ja) 2009-03-26
AU2006304790A1 (en) 2007-04-26
AU2006304790B2 (en) 2013-06-27
IL190773A (en) 2012-06-28
CN101351225B (zh) 2013-09-25
CA2638899C (en) 2016-01-05
IL190773A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
HK1129063A1 (en) Tumor-targeted nanodelivery systems to improve early mri detection of cancer
GB0600682D0 (en) Improvements to doppler radar systems
EP2109689A4 (en) DETECTION OF THE PROXIMITY OF A MOLECULE
EP2032594A4 (en) GLYCYRRHETINIC ACID DERIVATIVES
IL198062A0 (en) Improvements relating to the detection of patterns
ZA201001878B (en) Improved detection of mage-a-expression
IL176240A0 (en) Methods and systems using relative sensing to locate targets
SI1858929T1 (sl) Diagnoza raka prostate
EP2147298A4 (en) PROOF OF CANCER MARKERS
IL198976A0 (en) Companion diagnostic assays for cancer therapy
EP2114432A4 (en) METHODS OF MAKING CANCERS MORE SENSITIVE TO CHEMOTHERAPEUTIC AGENTS USING CHIMERIC ISF35
GB0820309D0 (en) Detection of cancer
EP2119018A4 (en) METHOD FOR DETERMINISTIC REDUCTION OF SIGNAL FAULTS
GB0525541D0 (en) Detection of antibodies
HK1133161A1 (zh) 箱包件
EP2212874A4 (en) DEVICE FOR MONITORING AND LOCATING SEMI-TRAILERS
HK1110655A1 (en) Diagnostic signal processor
EP1856645A4 (en) TARGETS FOR THE DETECTION OF ISCHEMIA
GB0722582D0 (en) Early detection of sepsis
ZA200710929B (en) Detection of hepatotoxic cyanobacteria
GB0709044D0 (en) Signal detection
GB0515325D0 (en) Improvements relating to the detection of lower limb disease
GB2444777B (en) Detection of radiation
GB0604231D0 (en) Cancer detection system
IL190949A0 (en) Jn vivo detection of apoptosis

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171020